Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TBio-4101 |
Synonyms | |
Therapy Description |
TBio-4101 are tumor-derived autologous tumor infiltrating lymphocytes (TILs), which may induce killing of tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TBio-4101 | TBio4101|TBio 4101 | TBio-4101 are tumor-derived autologous tumor infiltrating lymphocytes (TILs), which may induce killing of tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05628883 | Phase I | Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | Recruiting | USA | 0 |
NCT06236425 | Phase I | Cisplatin + Pembrolizumab Aldesleukin Carboplatin + Fluorouracil + Pembrolizumab TBio-4101 Cyclophosphamide + Fludarabine Cisplatin + Fluorouracil + Pembrolizumab | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | Recruiting | USA | 0 |